Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
The Effect of Vitamin D on Copd Exacerbation: A Double Blind Randomized Placebo-Controlled Parallel Clinical Trial Publisher



Sanjari M1 ; Soltani A2 ; Habibi Khorasani A3 ; Zareinejad M4
Authors

Source: Journal of Diabetes and Metabolic Disorders Published:2016


Abstract

Background: To investigate the effect of supplementation of standard treatment (inhaled long-acting β2 agonists, anticholinergics and corticosteroids) with vitamin D on C reactive protein and pulmonary function tests in patients with COPD exacerbation. Methods: Design: Randomized, single-center, double-blind, placebo-controlled parallel trial. One teaching hospital Participants: 135 patients in pulmonary ward with moderate to severe COPD and exacerbations.120 patients fulfilled the study protocol. Interventions: Patients were randomly divided into three groups receiving 7 day treatment with 0.25 μg calcitriol daily (n=45), 50000 IU daily of vitamin D (n=45) or placebo (n=45). An independent nurse was responsible for allocation, preparation, and accounting of trial medications. Main Outcome measures: Maximal expiratory flow volume (FEV1) and forced volume capacity curves (FVC) and Modified Medical Research Council (MMRC) scale. Results: Out of 135 patients who were recruited consecutively, 45 patients randomly were randomly assigned in three groups (balance blocked randomization.15 patients were dropped out due to non-compliance for second PFT. Intention to treat analysis was carried out for 120 participants. The difference between before and after treatment FEV1 and FEV1/FVC ratio had no significant difference between treatment groups and placebo. (P=0.43, P=0.51, respectively)but clinical improvement was significant in patients who received calcitriol. No side effects were reported. Conclusions: Short term treatment with either calcitriol or 25(OH) 2Vit D didn't changed FEV1 or FVC in vitamin D sufficient patients with COPD exacerbation; nevertheless it can provide clinical benefit. Trial registration: Trial registration: Iranian Registry of Clinical Trials no. IRCT138712271774N1. Registered 10 April 2011. © 2016 The Author(s).
Other Related Docs